NICE recommends Alnylam's Onpattro (patisiran) to treat multiple neuropathy caused by amyloid degeneration

The National Institute for Health and Clinical Excellence (NICE) has recently issued a positive opinion recommending http:// adrug(http:// http:// at theof the of AlnylamPharmaceuticals
( http://
)onthe," as an cost-effective treatment option for the NHS in england to treat adult patients with multiple neuropathy caused by hereditary transthyroidprotein (hATTR)Onpattro
Onpattro is an intravenous RNAi drug that targets thyroxine-carrying proteins (TTR)Onpattro aims to target and silence the specific messenger RNA (mRNA), blocking the production of TTR proteins, which may help reduce deposition and promote the removal of TTR amyloid proteins in peripheral tissues and restore the function of these tissuesOnpattro was approved by the United States and the European Union in August 2018, becoming the first RNAi drug to be approved for the year in 20 yearshATTR is a carrional, life-threatening disease that Onpattro addresses by reducing the production of abnormal proteins that damage nerves and organs throughout the bodyIn the critical phase III APOLLO study, 56 percent of patients treated with Onpattro for hATTR multiple neuropathy showed an improvement in neuropathy symptoms, compared with only 4 percent in the placebo groupIn addition, the latest data released in June 2019 showed that follow-up data on patients who received Onpattro treatment for 30-36 months showed that onpattro's post-treatment neuropathy impairment and improvement in quality of life was maintained during treatment